Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection

Clinical Infectious Diseases

Volumn 62, Issue 5, 2016, Pages 574-580

  Sheitoyan Pesant, Caroline ^a   Abou Chakra, Claire Nour ^a   Pépin, Jacques ^a   Marcil Héguy, Anaïs ^a   Nault, Vincent ^a   Valiquette, Louis ^a  

^a UniversitCrossed D Sign de Sherbrooke ^*  (Canada)

Author keywords

Clostridium difficile; Complications; Recurrence

Indexed keywords

CYTOTOXIN; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASSAY; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE MANAGEMENT; HOSPITAL ADMISSION; HUMAN; ILEUS; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERFORATION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; TOXIC MEGACOLON; COST OF ILLNESS; ECONOMICS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HOSPITALIZATION; INCIDENCE; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CANADA; CLOSTRIDIUM DIFFICILE; COHORT STUDIES; COST OF ILLNESS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HOSPITALIZATION; INCIDENCE; METRONIDAZOLE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN;

EID: 84960113829     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ958     Document Type: Article

References (32)

1. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012; 18(suppl 6):S21-7.
2. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
3. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada and the USA: a double-blind, non inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281-9.
4. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
5. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205.
6. Soriano MM, Danziger LH, Gerding DN, Johnson S. Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis 2014; 1:ofu069.
7. Abou Chakra CN, Pépin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014; 9:e98400.
8. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324-33.
9. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-8.
10. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20:43-50.
11. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-7.
12. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-75.
13. Laffan AM, Bellantoni MF, Greenough WB III, Zenilman JM. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J Am Geriatr Soc 2006; 54:1068-73.
14. Pawar D, Tsay R, Nelson DS, et al. Burden of Clostridium difficile infection in longterm care facilities in Monroe County, New York. Infect Control Hosp Epidemiol 2012; 33:1107-12.
15. Olsen MA, Yan Y, Reske KA, Zilberberg M, Dubberke ER. Impact of Clostridium difficile recurrence on hospital readmissions. Am J Infect Control 2015; 43: 318-22.
16. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
17. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28:140-5.
18. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 17:466-72.
19. Pépin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
20. Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-64.
21. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102:2781-8.
22. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55 (suppl 2):S77-87.
23. Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med 2011; 124:1081.e1-7.
24. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994; 15:371-81.
25. Heimann SM, Vehreschild JJ, Cornely OA, et al. Economic burden of Clostridium difficile associated diarrhea: a cost-of-illness study from a German tertiary care hospital. Infection 2015; 43:707-14.
26. Aitken SL, Joseph TB, Shah DN, et al. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One 2014; 9:e102848.
27. Zilberberg MD, Shorr AF, Micek ST, Kollef MH. Clostridium difficile recurrence is a strong predictor of 30-day rehospitalization among patients in intensive care. Infect Control Hosp Epidemiol 2015; 36:273-9.
28. Louie TJ, Miller MA, Crook DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013; 61:222-30.
29. Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 2012; 50:4078-82.
30. Institut National de Santé Publique du Québec. Clostridium difficile-associated diarrhiea (CDAD) surveillance results: 2012-2013, 2003-2013. Available at: https://www.inspq.qc.ca/pdf/publications/1878-Clostridium-difficile-Diarrhea-Vol1-No3.pdf. Accessed 26 November 2015.
31. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55(suppl 2):S154-61.
32. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014; 58:1507-14.